I-MAB (IMAB) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
I-Mab, a global biotech firm focused on cancer immunotherapies, has appointed Sean Fu as its permanent CEO. With over 20 years in the life sciences industry, Fu aims to advance I-Mab’s clinical programs and strategy. His leadership is expected to drive the company towards significant milestones in the development of transformative therapies.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
